Actively Recruiting
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
Led by Hansoh BioMedical R&D Company · Updated on 2025-04-09
780
Participants Needed
1
Research Sites
102 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.
CONDITIONS
Official Title
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males or females aged 18 to 75 years (inclusive)
- Histologically confirmed unresectable, recurrent, or metastatic solid tumors
- At least one measurable target lesion per RECIST v1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy greater than 12 weeks
- Use of adequate contraceptive measures throughout the study for males and females
- Females must not be pregnant at screening and should have no evidence of childbearing potential
- Signed informed consent form
You will not qualify if you...
- Received or are receiving anticancer therapies targeting MET, including tyrosine kinase inhibitors (TKIs), antibodies, or antibody-drug conjugates
- Received monoclonal or bispecific antibodies targeting EGFR
- Systemic anticancer treatments, including cytotoxic therapies, traditional Chinese medicine anticancer agents, or TKIs within 2 weeks prior to first HS-20117 dose
- Investigational anticancer drugs, antibodies, or antibody-drug conjugates within 4 weeks prior to first HS-20117 dose
- Local radiotherapy within 2 weeks prior to first HS-20117 dose, or more than 30% bone marrow irradiation or large-area radiotherapy within 4 weeks prior
- Presence of pleural effusion or ascites requiring intervention, or pericardial effusion
- Major surgery within 4 weeks prior to first HS-20117 dose
- Grade 2 or higher toxicities from prior antitumor therapy
- Uncured secondary primary malignancies
- Untreated or active central nervous system metastases
- Severe, uncontrolled, or active cardiovascular disorders
- Serious infection within 4 weeks prior to first HS-20117 dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Actively Recruiting
Research Team
X
Xiaowei Yan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here